Latest Breaking News On - Lora grassilli - Page 1 : comparemela.com

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesTed jenkinsKamal hamedLora grassilliDepartment of healthNational institute of allergyNational institutes of healthCenters for diseaseZeno groupWarfighter medical research program under award noDepartment of defenseDrug administrationOffice of theWorld health organizationHealth affairs

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomTed jenkinsLora grassilliSpero therapeutics incCompensation committee of spero board directorsZeno groupHealth media relationsCompensation committeeSpero therapeuticsEquity incentive planNasdaq listing ruleNasdaq listingRelations contactInvestor relationsHealth media

Spero Therapeutics Provides Corporate Update and 2024

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in.

United kingdomUnited statesLora grassilliTed jenkinsSath shuklaNational institutes of healthExchange commissionBiomedical advanced researchTebipenem hbr researchWarfighter medical research program under award noGovernment agency researchDevelopment authorityHuman servicesDepartment of defenseOffice of theAdministration for strategic preparedness

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLora grassilliTed jenkinsSath shuklaExchange commissionAdministration for strategic preparednessHealth media relationsDevelopment authorityMeiji seika pharma coUs department of healthTebipenem hbr researchHuman servicesBiomedical advanced researchDrug administrationZeno group

Spero Therapeutics Announces First Patient, First Visit for

$95 million in development milestones payable over two years, as part of GSK license agreement.

United statesUnited kingdomLora grassilliSath shuklaTed jenkinsTebipenem hbr researchUs department of healthExchange commissionHealth media relationsZeno groupBiomedical advanced researchMeiji seika pharma coAdministration for strategic preparednessDevelopment authoritySpero therapeutics incDrug administration